Rathbones Group PLC Has $77.07 Million Position in Stryker Corporation $SYK

Key Points

• Rathbones Group PLC boosted its stake in Stryker by 647.9%, adding 189,948 shares to hold 219,265 shares worth $77.07 million (about 0.06% of the company).
• Stryker beat fourth‑quarter estimates with EPS of $4.47 versus $4.40 and revenue of $7.17 billion (up 11.4% year‑over‑year), and analysts rate the stock a Moderate Buy with an average price target of $427.50.
• Director Ronda E. Stryker sold 250,000 shares for roughly $90.73 million, while insiders own 5.9% and institutions hold about 77.09%; the company also declared a quarterly dividend of $0.88 (annual yield ~1.1%).

Rathbones Group PLC lifted its holdings in shares of Stryker Corporation (NYSE:SYK - Free Report) by 647.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 219,265 shares of the medical technology company's stock after acquiring an additional 189,948 shares during the period. Rathbones Group PLC owned approximately 0.06% of Stryker worth $77,065,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Czech National Bank boosted its position in Stryker by 3.9% in the fourth quarter. Czech National Bank now owns 90,755 shares of the medical technology company's stock worth $31,898,000 after purchasing an additional 3,366 shares during the last quarter. Davis R M Inc. increased its position in shares of Stryker by 1.8% during the 3rd quarter. Davis R M Inc. now owns 138,732 shares of the medical technology company's stock valued at $51,285,000 after purchasing an additional 2,512 shares during the last quarter. Terra Alpha Investments LLC bought a new stake in shares of Stryker during the 3rd quarter worth $1,216,000. Kepler Cheuvreux Suisse SA purchased a new position in shares of Stryker in the 3rd quarter worth about $27,952,000. Finally, Diversified Trust Co grew its position in Stryker by 45.6% during the third quarter. Diversified Trust Co now owns 12,445 shares of the medical technology company's stock valued at $4,601,000 after buying an additional 3,899 shares during the period. 77.09% of the stock is owned by hedge funds and other institutional investors.

Stryker Stock Down 0.0%

SYK opened at $331.48 on Monday. Stryker Corporation has a 12 month low of $319.32 and a 12 month high of $404.87. The company has a market cap of $126.95 billion, a PE ratio of 39.46, a price-to-earnings-growth ratio of 1.94 and a beta of 0.92. The company has a current ratio of 1.89, a quick ratio of 1.21 and a debt-to-equity ratio of 0.66. The company has a 50 day moving average of $357.10 and a 200 day moving average of $361.76.

Stryker (NYSE:SYK - Get Free Report) last posted its earnings results on Thursday, January 29th. The medical technology company reported $4.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.40 by $0.07. Stryker had a return on equity of 24.41% and a net margin of 12.92%.The firm had revenue of $7.17 billion for the quarter, compared to the consensus estimate of $7.12 billion. During the same quarter in the prior year, the business posted $4.01 earnings per share. The business's quarterly revenue was up 11.4% on a year-over-year basis. On average, sell-side analysts expect that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, April 30th. Investors of record on Tuesday, March 31st will be issued a dividend of $0.88 per share. The ex-dividend date of this dividend is Tuesday, March 31st. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. Stryker's dividend payout ratio is 41.90%.

Insider Transactions at Stryker

In other Stryker news, Director Ronda E. Stryker sold 250,000 shares of the firm's stock in a transaction dated Wednesday, February 4th. The stock was sold at an average price of $362.92, for a total value of $90,730,000.00. Following the completion of the transaction, the director owned 2,457,331 shares in the company, valued at $891,814,566.52. This trade represents a 9.23% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 5.90% of the company's stock.

Analysts Set New Price Targets

SYK has been the subject of a number of research analyst reports. Truist Financial decreased their price objective on shares of Stryker from $400.00 to $392.00 and set a "hold" rating for the company in a report on Thursday, December 18th. BTIG Research increased their target price on shares of Stryker from $410.00 to $412.00 and gave the company a "buy" rating in a research report on Friday, January 30th. Piper Sandler restated an "overweight" rating on shares of Stryker in a research note on Tuesday, January 27th. William Blair reaffirmed an "outperform" rating on shares of Stryker in a report on Thursday, March 5th. Finally, Needham & Company LLC upped their price objective on Stryker from $448.00 to $454.00 and gave the company a "buy" rating in a research note on Friday, January 30th. Fourteen analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company's stock. According to MarketBeat.com, Stryker has an average rating of "Moderate Buy" and an average price target of $427.50.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.